logo.jpg
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
August 11, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18th 12:30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:...
logo.jpg
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
July 13, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE...
logo.jpg
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 09:15 ET | Vallon Pharmaceuticals Inc.
- Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple...
logo.jpg
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
May 11, 2021 09:05 ET | Vallon Pharmaceuticals Inc.
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 ...
logo.jpg
Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
May 07, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:...
logo.jpg
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...
logo.jpg
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 - Novel abuse-deterrent platform...
logo.jpg
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021 08:35 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
logo.jpg
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
February 23, 2021 09:05 ET | Vallon Pharmaceuticals Inc.
- Accomplished executive leader with more than 30 years of experience in finance and operations PHILADELPHIA, PA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON),...
logo.jpg
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021 15:30 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...